Nasdaq Markets

Few stocks have been hit as hard by the coronavirus pandemic as Lyft (NASDAQ: LYFT).

If you bought shares of Altimmune, (NASDAQ: ALT) Vaxart, (NASDAQ: VXRT) or Novavax (NASDAQ: NVAX) at the start of this year, you're already well on your way to riches. Thanks to the market's coronavirus vaccine frenzy, each of these companies' stock prices has exploded by more t

Chances are, Social Security will end up serving as an important income source for you during retirement. But if you're not well-versed on the following points of information, your financial plans could end up getting thrown for a loop.

Image source: Getty Images

Those who own shares of Gilead Sciences (NASDAQ: GILD) have been on quite the roller coaster ride this year. The stock reached a high in April as investors became optimistic about the company's new drug, remdesivir, and its potential to treat COVID-19 patients. On May 1, the U.

Investors without a fortune to invest traditionally found themselves in a difficult position. The problem: Some stocks that many people would like to buy are very expensive. Take Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), for example. The parent company of Google carries a price

One of the reasons investors are cautious about buying pot stocks is that many cannabis companies aren't profitable. Indeed, there's a danger that some will go out of business. And so when Tilray (NASDAQ: TLRY) released its latest results earlier this month featuring a signific

Living through a stock market crash is one of the most harrowing experiences for an investor. Watching your portfolio drop day after day after day -- after day -- can make even the most committed long-term investors doubt their choices. The market will recover eventually, but yo

Growth stocks are a great way to increase your portfolio's value over the long term. Investors love companies that continue to expand their reach and add to their sales numbers, because it usually means they're doing something right and their products and services are in high de

While the potential rewards in the pharmaceutical industry are high, so too is the rate of failure for companies trying to develop new drugs and therapies. But using artificial intelligence systems in the process can help improve those odds, and pharmaceutical companies are catc

As of today, 167 COVID-19 vaccine candidates are in development around the world with 28 in clinical human trials. Companies, nonprofits, and governments are partnering to find a safe and effective vaccine against the virus, which has resulted in nearly 750,000 deaths globally a

Small wonder Tesla (NASDAQ: TSLA) is planning a five-for-one stock split: its stock has skyrocketed more than 270% since the start of the year! With the split imminent, many investors are thinking about piling into the company's expensive shares in hopes that a lower post-spli

Image source: The Motley Fool.

Image source: The Motley Fool.

Image source: The Motley Fool.

The COVID-19 outbreak shouldn't have terrible news for games company Hasbro (NASDAQ: HAS).

Image source: The Motley Fool.

If Moderna (NASDAQ: MRNA) and its peers take too long to get their current coronavirus vaccine candidates fully developed and approved, they could pay the price. The government is mandating that they meet ambitious targets for this. If not, they'll receive reduced payments from

Most of the tech giants have reported Q2 earnings but one marquee name has yet to present its quarterly statement. Next Wednesday, August 19, GPU heavyweight Nvidia (NVDA) will report F2Q21 results.

Nvidia has been one of the main beneficiaries of the viral outbreak’s consequences. The WFH culture and shelter in place measures inadvertently played into Nvidia’s two core strengths – Data Center and Gaming.

Looking ahead to the print, Rosenblatt analyst Hans Mosesmann expects Nvidia to deliver the goods and anticipates the company will post “a slight beat.”

The latest report will also mark the first full quarter in which the impact of newly acquired data specialist Mellanox will come into play.

Driven by the pandemic’s tailwinds, Mosesmann anticipates “continued momentum” in Data Center and with the addition of Mellanox expects “low teens quarter-over-quarter growth.” The 5-star analyst cites “increased demand from work-from-home dynamics, solid backlog and visibility, and strong traction from the new Ampere,” as reasons to be confident in the segment’s performance.

The Mellanox acquisition was a significant milestone and is expected to make up 12% of total revenue, strongly contributing to Data Center growth.

As for Gaming, Mosesmann predicts a “low single-digits quarter-over-quarter uptick,” driven by COVID-19 and the shift to e-tail channels. These will be slightly offset by the closure of retail stores.

Mosesmann also expects Nvidia’s Automotive segment to offset the overall positivity. So do Nvidia management, who have guided for a 40% quarter-over-quarter decline.

But looking ahead, Mosesmann expects Nvidia’s out sized performance (up a whopping 94% year-to-date) to continue and guides for “mid-single-digit q/q growth,” in the October quarter.

Summing up, the 5-star analyst said, “We see Nvidia well positioned to take advantage of key themes/trends over the next few quarters, including continued transition to software defined data center architectures, which includes both Ampere GPU compute momentum and the emergence of data processing (DPUs offloading of traditional CPU workloads) and the new gaming version of the 7nm Ampere GPU.”

Accordingly, Mosesmann reiterated a Buy on NVDA shares alongside a $500 price target. The implication for investors? Upside of 8%. (To watch Mosesmann’s track record, click here)

As far as Nvidia’s rating goes, the rest of the Street and Mosesmann are on the same page. Based on 26 Buys, 3 Holds and 1 Sell, Nvidia boasts a Strong Buy consensus rating. However, where price targets are concerned, the two diverge. Overall, going by the $415 average price target, Mosesmann’s colleagues expects the share price to decline by 9% in the year ahead. (See Nvidia stock analysis on TipRanks)

Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.